Tuesday , 21 August 2018

Home » RESOURCES » INVESTING » AstraZeneca lung cancer drug meets late-stage trial endpoint

AstraZeneca lung cancer drug meets late-stage trial endpoint

AstraZeneca’s lung cancer treatment met its primary endpoint in a phase 3 trial, the company said early Monday. The drug, TAGRISSO, was tested on more than 400 patients with certain types of non-small cell lung cancers as a second-line treatment, with the results compared to standard platinum-based doublet chemotherapy. AstraZeneca is trading slightly higher in pre-market trade. The stock rose 8.2% over the last three months, compared with a 3.2% rise in the S&P 500 .

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

AstraZeneca lung cancer drug meets late-stage trial endpoint Reviewed by on . AstraZeneca's lung cancer treatment met its primary endpoint in a phase 3 trial, the company said early Monday. The drug, TAGRISSO, was tested on more than 400 AstraZeneca's lung cancer treatment met its primary endpoint in a phase 3 trial, the company said early Monday. The drug, TAGRISSO, was tested on more than 400 Rating:
scroll to top